Cost-Effectiveness Analysis of the Unfractionated Heparin versus Low–Molecular-Weight Heparin in Hospitalized Patients with Stroke Due to Atrial Fibrillation in Shiraz, South of Iran

Abstract

Background—Patients with atrial fibrillation (AF) make a unique group of strokes. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are among the medications used for preventing
blood coagulation. This study was carried out aiming at analyzing the cost effectiveness of LMWH versus
UFH in hospitalized patients with stroke due to AF with respect to the Iranian population.
Methods—This randomized study was an economic evaluation of cost effectiveness with the help of the
cross-sectional data of 2013–2015. In this study, 74 patients had undergone treatment in two groups, before
being evaluated. Half of the patients were treated by LMWH, while the other half was treated by UFH.
Effectiveness criterion was prevention of new stroke recurrence.
Results—Average medical direct costs, non-medical direct costs, and indirect costs of UFH were 110375
± 40411$, 15594 ± 11511$, and 21723 ± 19933$, respectively. Same average medical direct costs, nonmedical direct costs, and indirect costs of LMWH were 99573 ± 59143$, 9016 ± 17156$, and 10385 ±
10598$, respectively. The number of prevention of new strokes due to AF in LMWH and UFH was 2 and
0, respectively. Expected effectiveness in LMWH and UFH groups was 0.56 and 0.51, respectively. Moreover, the expected costs were 26737.61$ and 30776.18$, respectively. The incremental cost-effectiveness
ratio for stroke due to AF was −150, 201, 26$ per prevention of stroke recurrence (p-values ≤ 0/05).
Conclusion—The results of the cost-effectiveness analysis of LMWH versus UFH showed that LMWH
is a dominant strategy for patients with stroke due to AF in Iranian population.